{'fraction_non_alphanumeric': 0.023340627279358133, 'fraction_numerical': 0.0087527352297593, 'mean_word_length': 5.236363636363636, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Experimental study on 5-FU intraperitoneal injection for liver metastasis].

The 5-FU concentrations in peripheral blood and portal blood were determined in rats after 5-FU injection via three routes. Rats were given 1 ml of 5-FU (250 mg/kg) via the subphrenic, Douglas or intravenous routes. From comparison of 5-FU concentrations between the intravenous injection group and the intraperitoneal group (subphrenic injection group + Douglas injection group), the intraperitoneal group had a lower concentration than the intravenous one in peripheral blood. The intraperitoneal group showed a higher concentration than the intravenous one in portal blood. The intraperitoneal group was divided into two groups, a subphrenic injection group and a Douglas injection group. Though there was no significant difference between the 2 groups in the 5-FU concentrations in portal blood, the 5-FU concentration of peripheral blood in subphrenic injection group was significantly higher than in the Douglas injection group. It was conceivable that the subphrenic injection group had another absorption route from the abdominal cavity to the peripheral blood. Accordingly, the intraperitoneal injection of the agent may be useful therapy for liver metastasis. However, due care must be given to the injection lesion in the abdominal cavity, the concentration and volume of the agent.